



Cancer Metastasis and Therapeutic Resistance

Guest Editor:

Dr. Elizabeth Shinmay Yeh

Department of Pharmacology
and Toxicology, Indiana
University School of Medicine,
Simon Comprehensive Cancer
Center, Indianapolis, IN, USA

Deadline for manuscript
submissions:

closed (30 September 2022)

Message from the Guest Editor

Dear Colleagues,

Metastasis and resistance to cancer treatments often go hand in hand, relying on overlapping mechanisms that allow cancer to progress from their primary form to more severe disease states. These mechanisms include the activation of signaling pathways, evasion of immune surveillance, and alteration of cell surface receptors. While numerous targets and agents have been uncovered in recent years, cancer cells continue to evade these solutions. In this Special Issue, we aim to present high-quality research in these areas to share within the research community what we have learned, what is new, and what is on the cutting edge of mechanisms that cause metastasis and resistance. We welcome the submission of original research articles and review articles on signaling mechanisms, experimental therapeutics, and clinical observations.

Dr. Elizabeth Yeh

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)